Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | Investigational |
| Human amounts | Trial dosesDosing reference Study durations |
| Format | Lyophilized vial |
| Type | Single compound |
| Molecular formula | C192H289N47O61 |
| Molecular weight | 4,232 g/mol |
| CAS number | Not listed |
| Sequence | Not listed |
| References | 19 |
| Summary | Survodutide (BI 456906) is an investigational once-weekly peptide that activates both the glucagon and GLP-1 receptors. It has been studied in phase 2 and phase 3 randomized trials in obesity, type 2 diabetes and fatty liver disease. It is not an approved medicine, and this entry is for research information only. |